Probiotic Composition Modifies Intestinal Microbiota to Treat Psoriasis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for psoriasis often come with significant side effects and economic costs, and there is a need for effective compounds that do not cause these issues, as the disease's pathogenesis is not well understood and traditional treatments like immunosuppressants can lead to adverse effects.
Innovation Solution
A probiotic composition comprising Bifidobacterium animalis subsp. lactis (B. lactis) CECT 8145, Bifidobacterium longum ES1 CECT 7347, and Lactobacillus rhamnosus CECT 8361, which modifies the intestinal microbiota, is used to treat and prevent psoriasis by improving intestinal diversity, thereby alleviating symptoms and reducing disease progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immunosuppressants are used to treat psoriasis, then the inflammatory component is suppressed and symptoms are alleviated, but side effects occur including latent infectious diseases and antibody phenomenon
Solution Approach 1:
The patent introduces probiotics as an intermediary substance that mediates the treatment of psoriasis through the gut-skin axis. Instead of directly suppressing immunity with immunosuppressants, the probiotics modify intestinal microbiota composition, which indirectly regulates immune function and reduces inflammation in psoriasis patients, thereby avoiding direct immunosuppression side effects
Solution Approach 2:
The patent replaces the mechanical/chemical approach of direct immunosuppression with a biological approach using probiotics. The treatment mechanism shifts from direct drug-receptor interaction to microbiota-mediated immune modulation, substituting conventional pharmacological intervention with a biological therapy that leverages the gut-skin axis
2Reliability
If anti-TNF and monoclonal anti IL-23 drugs are used, then treatment effectiveness is improved, but economic cost increases and side effects occur
Solution Approach 1:
The patent employs probiotics as a cost-effective alternative to expensive biologic drugs. Probiotics are significantly cheaper to produce and administer compared to anti-TNF and monoclonal anti IL-23 therapies. The probiotic composition can be administered orally and provides sustained benefit through microbiota modification, eliminating the need for continuous expensive injections
Solution Approach 2:
The probiotics serve as an intermediary that addresses the root cause of psoriasis through gut-skin axis modulation rather than directly blocking inflammatory pathways. This indirect approach through microbiota regulation may provide more sustainable long-term efficacy without the resistance issues seen with direct immunomodulators
3Duration of action of stationary object
If conventional psoriasis treatments are used, then symptoms are controlled, but the disease shows relapse over time due to antibody phenomenon
Solution Approach 1:
The patent applies preliminary action by modifying the intestinal microbiota before psoriasis symptoms fully develop or recur. By establishing a healthy gut microbiota composition through probiotics, the treatment prevents the immune dysregulation that leads to psoriasis flares, addressing the root cause before clinical manifestation occurs
Solution Approach 2:
The probiotics enable the patient's own microbiota to serve the therapeutic function of regulating immune response. Once the probiotic bacteria are established in the gut, they continuously modulate the immune system and maintain disease remission without requiring ongoing external intervention, creating a self-sustaining therapeutic effect
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention is intended for the use of a probiotic composition comprising Bifidobacterium animalis subs, lactis (B. lactis), Bifidobacterium longum and Lactobacillus rhamnosus, in particular the strains B. lactis CECT 8145, B. longum ES1 CECT 7347 and/or L. rhamnosus CECT 8361, in the treatment and/or prevention of psoriasis outbreaks or psoriasis.